# PFIZER INC

> Cross-vertical US regulatory timeline. Last 180 days. 100 events.

**Ticker:** PFE · **SEC CIK:** 0000078003

## Vertical activity

| Vertical | Event count |
|---|---:|
| clinical | 100 |
| sec | 10 |
| dol | 2 |
| contracts | 1 |
| open | 1 |

## Timeline (newest first)

- **2026-07-01** `sec.filing` — 4 — BOURLA ALBERT — 2026-07-01 [importance=30]
- **2026-06-18** `sec.filing` — 8-K — PFIZER INC — 2026-06-18 [importance=35]
- **2026-06-18** `sec.filing` — 8-K — PFIZER INC — 2026-06-18 [importance=35]
- **2026-06-16** `sec.filing` — 11-K — PFIZER INC — 2026-06-16 [importance=30]
- **2026-06-16** `sec.filing` — 11-K — PFIZER INC — 2026-06-16 [importance=30]
- **2026-06-09** `sec.insider.s` — DAMICO JENNIFER B. — SVP & Controller [importance=35]
- **2026-05-18** `clinical.trial` — Pfizer — [Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe](https://api.ai-analytics.org/clinical/NCT04370054) [importance=60]
- **2026-05-18** `clinical.trial` — Pfizer — [A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)](https://api.ai-analytics.org/clinical/NCT07400653) [importance=60]
- **2026-05-18** `clinical.trial` — Pfizer — [A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesi](https://api.ai-analytics.org/clinical/NCT07400679) [importance=30]
- **2026-05-18** `clinical.trial` — Pfizer — [Vyndaqel Capsules Special Investigation (ATTR-CM)](https://api.ai-analytics.org/clinical/NCT04108091) [importance=25]
- **2026-05-18** `clinical.trial` — Pfizer — [A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.](https://api.ai-analytics.org/clinical/NCT07152119) [importance=25]
- **2026-05-15** `clinical.trial` — Pfizer — [A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised](https://api.ai-analytics.org/clinical/NCT07013474) [importance=60]
- **2026-05-15** `clinical.trial` — Pfizer — [A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies](https://api.ai-analytics.org/clinical/NCT06698796) [importance=60]
- **2026-05-15** `clinical.trial` — Pfizer — [This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide W](https://api.ai-analytics.org/clinical/NCT07028853) [importance=60]
- **2026-05-15** `clinical.trial` — Pfizer — [A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Sin](https://api.ai-analytics.org/clinical/NCT06866405) [importance=60]
- **2026-05-15** `clinical.trial` — Pfizer — [A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis](https://api.ai-analytics.org/clinical/NCT05287126) [importance=45]
- **2026-05-15** `clinical.trial` — Pfizer — [Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544](https://api.ai-analytics.org/clinical/NCT07563894) [importance=30]
- **2026-05-15** `clinical.trial` — Pfizer — [A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea](https://api.ai-analytics.org/clinical/NCT07497854) [importance=25]
- **2026-05-15** `clinical.trial` — Pfizer — [A Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone Deficiency (p GHD) in India.](https://api.ai-analytics.org/clinical/NCT06587035) [importance=25]
- **2026-05-15** `clinical.trial` — Pfizer — [Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy](https://api.ai-analytics.org/clinical/NCT06647654) [importance=25]
- **2026-05-14** `clinical.trial` — Pfizer — [BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies](https://api.ai-analytics.org/clinical/NCT07160244) [importance=60]
- **2026-05-14** `clinical.trial` — Pfizer — [A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratum](https://api.ai-analytics.org/clinical/NCT05623020) [importance=60]
- **2026-05-14** `clinical.trial` — Pfizer — [A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.](https://api.ai-analytics.org/clinical/NCT07543380) [importance=60]
- **2026-05-14** `clinical.trial` — Pfizer — [A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not H](https://api.ai-analytics.org/clinical/NCT06679140) [importance=60]
- **2026-05-14** `clinical.trial` — Pfizer — [A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With Firs](https://api.ai-analytics.org/clinical/NCT05748171) [importance=45]
- **2026-05-14** `clinical.trial` — Pfizer — [A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.](https://api.ai-analytics.org/clinical/NCT05355701) [importance=30]
- **2026-05-14** `clinical.trial` — Pfizer — [A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relap](https://api.ai-analytics.org/clinical/NCT06215118) [importance=30]
- **2026-05-14** `clinical.trial` — Pfizer — [A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fasting Conditions](https://api.ai-analytics.org/clinical/NCT07587697) [importance=30]
- **2026-05-14** `clinical.trial` — Pfizer — [A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC](https://api.ai-analytics.org/clinical/NCT07556549) [importance=25]
- **2026-05-14** `clinical.trial` — Pfizer — [Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)](https://api.ai-analytics.org/clinical/NCT06057402) [importance=25]
- **2026-05-14** `clinical.trial` — Pfizer — [A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for ](https://api.ai-analytics.org/clinical/NCT05742217) [importance=25]
- **2026-05-13** `clinical.trial` — Pfizer — [A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata](https://api.ai-analytics.org/clinical/NCT06873945) [importance=60]
- **2026-05-13** `clinical.trial` — Pfizer — [A Study to Learn How a Single Dose of the Study Medicine Called PF-08057418 is Tolerated in the Body of Healthy Adults.](https://api.ai-analytics.org/clinical/NCT07575906) [importance=30]
- **2026-05-12 16:12:04** `contracts.award` — Department of Health and Human Services — IGF::OT::IGF [importance=70]
- **2026-05-12** `clinical.trial` — Pfizer — [A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Signif](https://api.ai-analytics.org/clinical/NCT06989437) [importance=60]
- **2026-05-12** `clinical.trial` — Pfizer — [Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B R](https://api.ai-analytics.org/clinical/NCT05568719) [importance=60]
- **2026-05-12** `clinical.trial` — Pfizer — [Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia](https://api.ai-analytics.org/clinical/NCT05070845) [importance=45]
- **2026-05-12** `clinical.trial` — Pfizer — [A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have P](https://api.ai-analytics.org/clinical/NCT07073820) [importance=45]
- **2026-05-12** `clinical.trial` — Pfizer — [Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B](https://api.ai-analytics.org/clinical/NCT03307980) [importance=45]
- **2026-05-12** `clinical.trial` — Pfizer — [A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arteri](https://api.ai-analytics.org/clinical/NCT06137742) [importance=45]
- **2026-05-12** `clinical.trial` — Pfizer — [A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function](https://api.ai-analytics.org/clinical/NCT07269301) [importance=30]
- **2026-05-12** `clinical.trial` — Pfizer — [A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function](https://api.ai-analytics.org/clinical/NCT07315360) [importance=30]
- **2026-05-12** `clinical.trial` — Pfizer — [A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment](https://api.ai-analytics.org/clinical/NCT07567352) [importance=25]
- **2026-05-11** `clinical.trial` — Pfizer — [A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual ](https://api.ai-analytics.org/clinical/NCT06641466) [importance=60]
- **2026-05-11** `clinical.trial` — Pfizer — [Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult](https://api.ai-analytics.org/clinical/NCT07578649) [importance=60]
- **2026-05-11** `clinical.trial` — Pfizer — [Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects](https://api.ai-analytics.org/clinical/NCT05156398) [importance=60]
- **2026-05-11** `clinical.trial` — Pfizer — [A Study to Understand What the Body Does to the Study Medicine Called PF-07799544 When Taken by Healthy Adults](https://api.ai-analytics.org/clinical/NCT07578636) [importance=30]
- **2026-05-11** `clinical.trial` — Pfizer — [A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced So](https://api.ai-analytics.org/clinical/NCT05538130) [importance=30]
- **2026-05-11** `clinical.trial` — Pfizer — [A Study to Learn How Different Injector Pens Affect the Study Medicine Called Genotropin (Somatropin) Delivery and Taken](https://api.ai-analytics.org/clinical/NCT07542886) [importance=30]
- **2026-05-11** `clinical.trial` — Pfizer — [A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting](https://api.ai-analytics.org/clinical/NCT05452941) [importance=25]

## Provenance

This timeline merges events from these primary sources:

- **SEC EDGAR** — https://www.sec.gov/edgar (filings, insider transactions, Form 144, Schedule 13D/G)
- **openFDA** — https://api.fda.gov/ (recalls, drug labels)
- **USAspending** — https://api.usaspending.gov/ (federal contracts)
- **CourtListener** — https://www.courtlistener.com/ (federal court dockets)
- **CFPB** — https://www.consumerfinance.gov/data-research/consumer-complaints/ (consumer complaints)
- **NIH RePORTER** — https://api.reporter.nih.gov/ (grants)
- **Federal Reserve** — https://www.federalreserve.gov/supervisionreg/enforcementactions.htm (banking enforcement)
- **NHTSA** — https://api.nhtsa.gov/ (vehicle recalls)
- **DOJ** — https://www.justice.gov/news (press releases)
- **EPA ECHO** — https://echo.epa.gov/ (regulated facilities)
- **ClinicalTrials.gov** — https://clinicaltrials.gov/ (drug trials)
- **Senate LDA** — https://lda.senate.gov/ (lobbying disclosures)
- **OFAC** — https://sanctionslistservice.ofac.treas.gov/ (sanctions)

## Citation

> AI Analytics. Cross-vertical regulatory timeline for PFIZER INC. Retrieved 2026-09-21T07:31:57.337Z from https://api.ai-analytics.org/entity/PFE. Source terms: https://api.ai-analytics.org/license.

## Related

- [JSON timeline](https://api.ai-analytics.org/api/v1/entity/PFE/timeline?days=180)
- [Material events only](https://api.ai-analytics.org/api/v1/entity/PFE/material-events?days=180)
- [Compliance screen](https://api.ai-analytics.org/api/v1/screening/all?name=PFIZER%20INC)
- [All cross-vertical entities](https://api.ai-analytics.org/entity/)
- [Dataset catalog](https://api.ai-analytics.org/datasets/)

---

*AI Analytics · [Source-specific license and terms](https://api.ai-analytics.org/license) · Free or keyless access does not alter source terms.*